Back

Cell-specific crosstalk proteomics reveals cathepsin B signaling as a driver of glioblastoma malignancy near the subventricular zone

Norton, E. S.; Whaley, L. A.; Jones, V. K.; Brooks, M. M.; Russo, M. N.; Morderer, D.; Jessen, E.; Schiapparelli, P.; Ramos-Fresnedo, A.; Zarco, N.; Carrano, A.; Rossoll, W.; Asmann, Y. W.; Lam, T. T.; Chaichana, K. L.; Anastasiadis, P. Z.; Quinones-Hinojosa, A.; Guerrero-Cazares, H.

2023-08-21 cancer biology
10.1101/2023.08.19.553966 bioRxiv
Show abstract

Glioblastoma (GBM) is the most prevalent and aggressive malignant primary brain tumor. GBM proximal to the lateral ventricles (LVs) is more aggressive, potentially due to subventricular zone (SVZ) contact. Despite this, crosstalk between GBM and neural stem/progenitor cells (NSC/NPCs) is not well understood. Using cell-specific proteomics, we show that LV-proximal GBM prevents neuronal maturation of NSCs through induction of senescence. Additionally, GBM brain tumor initiating cells (BTICs) increase expression of CTSB upon interaction with NPCs. Lentiviral knockdown and recombinant protein experiments reveal both cell-intrinsic and soluble CTSB promote malignancy-associated phenotypes in BTICs. Soluble CTSB stalls neuronal maturation in NPCs while promoting senescence, providing a link between LV-tumor proximity and neurogenesis disruption. Finally, we show LV-proximal CTSB upregulation in patients, showing the relevance of this crosstalk in human GBM biology. These results demonstrate the value of proteomic analysis in tumor microenvironment research and provide direction for new therapeutic strategies in GBM. HighlightsO_LIPeriventricular GBM is more malignant and disrupts neurogenesis in a rodent model. C_LIO_LICell-specific proteomics elucidates tumor-promoting crosstalk between GBM and NPCs. C_LIO_LINPCs induce upregulated CTSB expression in GBM, promoting tumor progression. C_LIO_LIGBM stalls neurogenesis and promotes NPC senescence via CTSB. C_LI

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 24%
8.1%
2
Neoplasia
22 papers in training set
Top 0.1%
7.1%
3
Neuro-Oncology
30 papers in training set
Top 0.2%
6.2%
4
Cell Reports
1338 papers in training set
Top 8%
6.2%
5
Acta Neuropathologica Communications
81 papers in training set
Top 0.1%
4.8%
6
Cancer Cell
38 papers in training set
Top 0.4%
3.9%
7
Neuro-Oncology Advances
24 papers in training set
Top 0.2%
3.9%
8
Neurobiology of Disease
134 papers in training set
Top 2%
2.7%
9
Cancers
200 papers in training set
Top 2%
2.7%
10
Cell Reports Medicine
140 papers in training set
Top 2%
2.6%
11
Brain
154 papers in training set
Top 2%
2.1%
50% of probability mass above
12
Scientific Reports
3102 papers in training set
Top 51%
2.1%
13
Cell Reports Methods
141 papers in training set
Top 2%
1.7%
14
Cancer Research
116 papers in training set
Top 2%
1.7%
15
Cells
232 papers in training set
Top 3%
1.6%
16
eLife
5422 papers in training set
Top 44%
1.6%
17
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.6%
18
PLOS ONE
4510 papers in training set
Top 57%
1.5%
19
iScience
1063 papers in training set
Top 18%
1.5%
20
Clinical Cancer Research
58 papers in training set
Top 1%
1.2%
21
JCI Insight
241 papers in training set
Top 5%
1.2%
22
Glia
74 papers in training set
Top 0.4%
1.2%
23
Genome Medicine
154 papers in training set
Top 6%
1.2%
24
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 6%
1.2%
25
Clinical Epigenetics
53 papers in training set
Top 0.7%
1.2%
26
The EMBO Journal
267 papers in training set
Top 3%
1.2%
27
Acta Neuropathologica
51 papers in training set
Top 1.0%
0.9%
28
Molecular Oncology
50 papers in training set
Top 0.8%
0.9%
29
Advanced Science
249 papers in training set
Top 19%
0.7%
30
Journal of Clinical Investigation
164 papers in training set
Top 7%
0.7%